Lortinib 150mg Tablet 10?S Allschoolabs -

Description

INTRODUCTION
LORTINIB 150MG TABLET contains Erlotinib which belongs to the group of medicines called Kinase inhibitors. It is used in adults to treat non-small cell lung cancer at an advanced stage, as initial therapy (or as therapy if disease remains largely unchanged after initial chemotherapy, provided your cancer cells have specific EGFR mutations).
It is also used if previous chemotherapy has not helped to stop the disease and to treat cancer of the pancreas at a metastatic stage in combination with gemcitabine. Cancer can be defined as body cells beginning to grow out of control. Cells in any part of the body can become cancer cells and can spread to other areas of the body. Your doctor may perform certain blood tests prior to the treatment.
Avoid smoking during the treatment of LORTINIB 150MG TABLET, as it decreases the effect of the medicine. LORTINIB 150MG TABLET is not recommended for use if you have severe liver or kidney disease. Before taking LORTINIB 150MG TABLET inform your doctor if you have diarrhea, glucuronidation disorder like Gilbert?s syndrome, history of peptic ulcers or diverticular disease, you use contact lenses, or have a history of eye problems (severe dry eyes, inflammation or ulcers of the cornea).
LORTINIB 150MG TABLET is generally not recommended for use in pregnant and breastfeeding women unless considered clearly necessary, therefore consult your doctor before taking it. LORTINIB 150MG TABLET is not recommended for use in children and adolescents below 18 years of age. The most common side effects of taking LORTINIB 150MG TABLET are rash, infection, loss of appetite, decreased weight, or depression. Contact your doctor if any of the symptoms worsen.
USES OF LORTINIB 150MG TABLET
Treats:
Non-small cell lung cancer at an advanced stage

Initial cancer stage (or as therapy if disease remains largely unchanged after initial chemotherapy)

Pancreatic cancer at a metastatic stage in combination with gemcitabine

HOW LORTINIB 150MG TABLET WORKS
LORTINIB 150MG TABLET binds to the intracellular portion (tyrosine kinase) of the epidermal growth factor receptor (EGFR) and inhibits its activity. EGFR is expressed on the surface of both normal as well as cancer cells. Inhibition of EGFR and its signaling significantly decreases tumor multiplication and survival, resulting in cell death.
DIRECTIONS FOR USE
Take LORTINIB 150MG TABLET as advised by your physician. Swallow the medicine with a glass of water. Do not crush or chew the medicine. Do not take medicine with food. Your doctor will decide the correct dose and duration for you depending upon your age, body weight, and disease condition.
SIDE EFFECTS OF LORTINIB 150MG TABLET

COMMON

Rash which may occur or worsen in sun-exposed areas

Infection

Loss of appetite, decreased weight

Depression

Headache

Change in skin sensation or numbness in the extremities

Difficulty in breathing, cough

Nausea

Mouth irritation

Stomach pain, indigestion, and flatulence

Itching, dry skin

Loss of hair

Tiredness, fever, rigor

Bleeding from the nose, stomach, or the intestines

Inflammatory reactions around the fingernail

Infection of hair follicles

Acne

Cracked skin (skin fissures)

Reduced kidney function

UNCOMMON

Eyelash and eyebrow changes

Excess hair in the body and face of a male distribution pattern

Brittle and loose nails

RARE

Palmar plantar erythrodysaesthesia syndrome (flushed or painful palms or soles)
Stop taking LORTINIB 150MG TABLET and contact your doctor immediately if you experience any of the following side effects:
Persistent and severe diarrhea and vomiting

Eye irritation due to conjunctivitis/keratoconjunctivitis or keratitis

Interstitial lung disease (sudden difficulty breathing associated with cough or fever)

Gastrointestinal perforations (severe pain in the abdomen)

Acute or worsening redness and pain in the eye increased water in the eye, blurred vision, and/or sensitivity to light

Blistering or peeling of skin

Inflammation of the liver ( feeling of being unwell, with or without jaundice (yellowing of the skin and eyes), dark urine, nausea, vomiting and abdominal pain)

HOW TO MANAGE SIDE EFFECTS
Nausea:
Stick to simple meals. Avoid eating oil rich or spicy foods, sugary snacks and drinks. Avoid drinking too much liquid along with your meals, drink slowly in between meals. Inform your doctor if the condition worsens.
Headache:
Take some rest, in a quiet place and avoid using mobile phones and other electronic devices for a while. Drink water as inadequate hydration may worsen your headache. If symptoms persist, contact your doctor.
Stomach pain:
Rest and relax. Try to have smaller meals but take them frequently. Keep a heat pad on your stomach. Do not self-treat and contact your doctor if the symptom did not improve.
Flatulence:
Eat smaller and more frequent meals. Eat and drink slowly and exercise regularly. If the symptoms do not improve, contact your doctor.
Loss of appetite:
Eat when you are hungry. Eat smaller meals more often than usual. Snack only when you?re hungry. Eat a nutritious snack which is rich in calories and protein, such as dried fruit and nuts.
WARNING & PRECAUTIONS

PREGNANCY
There is no adequate data on the use of LORTINIB 150MG TABLET in pregnant women. If you become pregnant during the treatment immediately inform your doctor who will decide if the treatment should be continued.
Use adequate contraception during treatment, and for at least 2 weeks after taking the last medicine. Consult your doctor before taking LORTINIB 150MG TABLET.
BREASTFEEDING
LORTINIB 150MG TABLET is not recommended for use in breastfeeding women and for at least 2 weeks after taking the last medicine. Consult your doctor before taking LORTINIB 150MG TABLET.
DRIVING AND USING MACHINES
LORTINIB 150MG TABLET is unlikely to affect your ability to drive or use machines.
KIDNEY
LORTINIB 150MG TABLET is generally not recommended to use in patients with severe kidney disease. Consult your doctor before taking LORTINIB 150MG TABLET.
LIVER
LORTINIB 150MG TABLET is generally not recommended to use in patients with severe liver disease. Consult your doctor before taking LORTINIB 150MG TABLET.
ALLERGY
Do not take LORTINIB 150MG TABLET if you are allergic to Erlotinib or any of the other ingredients of the medicines.
OTHERS
Before taking LORTINIB 150MG TABLET, inform your doctor if you have:
Contact lenses

History of eye problems such as severe dry eyes, inflammation or ulcers of the front part of the eye (cornea)

Diarrhea

History of peptic ulceration or diverticular disease

Glucuronidation disorder like Gilbert?s syndrome
Use in pediatrics:
LORTINIB 150MG TABLET is not recommended for use in children and adolescents (under 18 years of age). Consult your doctor before taking LORTINIB 150MG TABLET.
INTERACTIONS
A. Drug-Drug interactions:
Before taking LORTINIB 150MG TABLET, inform your doctor if you are taking any of the following medicine:
Ketoconazole (to treat fungal infections)

Erythromycin, clarithromycin, and ciprofloxacin (antibacterial agents)

Protease inhibitors like atazanavir, idinavir (to treat HIV)

Warfarin (to prevent blood clotting)

Statins (Ex. atorvastatin, rosuvastatin, simvastatin) to lower blood cholesterol

Phenytoin, carbamazepine (treats epilepsy or fits)

Omeprazole, ranitidine (reduces stomach acid)

Rifampicin (treats tuberculosis)

St. John?s Wort (treats depression)

Barbiturates (used to treat seizures)
Overdosage:
If you or anyone else accidentally takes too much LORTINIB 150MG TABLET, consult your doctor immediately or visit the nearby hospital.
SYNOPSIS

Drug :?? Erlotinib

Pharmacological Category :?? Kinase inhibitors

Therapeutic Indication :?? Non-small cell lung cancer, initial cancer therapy and pancreatic cancer

Dosage Forms :?? Tablet

MORE INFORMATION

Keep LORTINIB 150MG TABLET out of reach of children

Store at room temperature

FAQs ABOUT LORTINIB 150MG TABLET
What is LORTINIB 150MG TABLET used for?
LORTINIB 150MG TABLET is used in adults to treat non-small cell lung cancer at an advanced stage, as initial therapy (or as therapy if disease remains largely unchanged after initial chemotherapy, provided your cancer cells have specific EGFR mutations), if previous chemotherapy has not helped to stop the disease and to treat cancer of the pancreas at a metastatic stage in combination with gemcitabine.
What is the mechanism of action of LORTINIB 150MG TABLET?
LORTINIB 150MG TABLET binds to the intracellular portion (tyrosine kinase) of the epidermal growth factor receptor (EGFR) and inhibits its activity. EGFR is expressed on the surface of both normal as well as cancer cells. Inhibition of EGFR and it?s signaling significantly decreases tumor multiplication and survival, resulting in cell death.
Can LORTINIB 150MG TABLET be used in pregnant women?
There is no adequate data on the use of LORTINIB 150MG TABLET in pregnant women. If you become pregnant during the treatment immediately inform your doctor who will decide if the treatment should be continued.
Can LORTINIB 150MG TABLET be taken along with Statins?
If you are taking statins (medicines to lower your blood cholesterol), LORTINIB 150MG TABLET may increase the risk of statin related muscle problems, which on rare occasions can lead to serious muscle breakdown (rhabdomyolysis) resulting in kidney damage, talk to your doctor before taking this medicine.
Can LORTINIB 150MG TABLET be used in children?
LORTINIB 150MG TABLET is not recommended for use in children and adolescents (under 18 years of age). Consult your doctor for more information on this medicine before taking it.
REFERENCES
1. Goodman & Gilman?s: The Pharmacological Basis of Therapeutics. 13th Edition. New York McGraw Hill Medical 2018 Page ? 863-886.
2. Jose Ramon Gonzalez-Porras and Jose Maria Bastida. Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety. National Library of Medicine, National Center for Biotechnology information. Pubmed Central.?June 2018. [Accessed on 13th May 2022]?https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971401/
3. Marco Dionisi, Sara Cairoli, Raffaele Simeoli, Francesca De Gennaro, Valeria Paganelli, Roberto Carta, Francesca Rossi, Carlo Dionisi-Vici, Giuseppe Palumbo and Bianca Maria Goffredo. Pharmacokinetic Evaluation of Eltrombopag in ITP Pediatric Patients. Journal of frontiers in pharmacology. December 2021 [Accessed on 13th May 2022] https://www.frontiersin.org/articles/10.3389/fphar.2021.772873/full
4. Roche Products Limited. Electronic Medicines Compendium (EMC). [Revised in November 2022]. [Accessed on 13th May 2022]?https://www.medicines.org.uk/emc/files/pil.8844.pdf
5. OSI Pharmaceuticals Inc. U.S Food and Drug Administration. [Revised in October 2016] [Accessed on 13th May 2022]?https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf
USEFUL DIAGNOSTIC TESTS